Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company pioneering viral immunotherapies for solid tumor treatment. This page serves as the definitive source for official updates on the company's innovative adenovirus and herpes simplex virus (HSV) platform developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing therapy advancements, peer-reviewed research collaborations, and manufacturing updates relevant to CADL's immuno-oncology pipeline.
Key content categories include phase trial results, FDA communications, intellectual property developments, and executive leadership announcements. All materials are sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page for streamlined access to Candel Therapeutics' latest developments in cancer immunotherapy. Check regularly for updates on their gmci™ and rqnestin34.5 platforms as they progress through clinical evaluation.
Candel Therapeutics will host a webcasted R&D breakfast panel during the 2024 ASCO Annual Meeting on June 3, 2024, at 7:00 AM Central Time. The event will focus on discussing topline overall survival data from the Phase 2 clinical trial of CAN-2409, a multimodal biological immunotherapy candidate for Non-Small Cell Lung Cancer (NSCLC). The panel, moderated by Candel's CEO Paul Peter Tak, will feature prominent medical and scientific leaders, including Dr. Charu Aggarwal from the University of Pennsylvania, Dr. Roy S. Herbst from Yale School of Medicine, and Dr. Daniel H. Sterman from NYU Langone Health. A live webcast and an archived replay will be available on Candel's website.
Candel Therapeutics (Nasdaq: CADL) reported its Q1 2024 financial results and corporate highlights. The company showcased positive survival data from its ongoing phase 2 clinical trial of CAN-2409 in pancreatic cancer, with a median overall survival of 28.8 months compared to 12.5 months for the control group. CAN-2409 also received FDA Fast Track and Orphan Drug Designations.
Topline survival data for CAN-2409 in NSCLC will be presented at ASCO on June 3, 2024. The company's enLIGHTEN™ platform revealed a new immunotherapy candidate at the AACR Annual Meeting.
Financially, Candel's Q1 2024 research and development expenses decreased to $4.1 million from $5.5 million in Q1 2023. General and administrative expenses also decreased to $3.8 million from $4.2 million. The net loss stood at $8.2 million, down from $8.8 million. Cash reserves were $25.7 million as of March 31, 2024, providing sufficient funds into Q4 2024.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
